BioGaia starts its own distribution in the UK
Beginning in November 2021, BioGaia will be selling its probiotic products under its own management in the UK market. The...
Read moreBioGaia Pharma secures approval for two clinical trials for its pharmaceutical candidates
BioGaia Pharma has received formal approval from relevant authorities to proceed with both of its planned clinical trials. The trials...
Read moreBioGaia research wins first prize at LAB Symposium
The prestigious International Symposium on Lactic Acid Bacteria was held between 23–25 August and gathered more than 300 participants....
Read moreBioGaia Interim report January – June 2021
Second quarter 2021 · Net sales amounted to SEK 203.1 million (244.7), a decrease of 17% (excluding foreign exchange...
Read moreWebinar July 13: What is the secret of healthy ageing?
What is the secret of healthy ageing? How can we ensure a long existence, while maintaining a high quality of...
Read moreBioGaia becomes full owner of MetaboGen
As per today, July 2, BioGaia becomes 100 percent shareholder of MetaboGen. Previously, BioGaia held 92 percent of the shares...
Read moreWebinar: Probiotics as invisible allies to promote our health and prevent diseases
Do you know that antimicrobial resistance has been declared as one of the top 10 public health threats for the...
Read moreBioGaia opens up new subsidiary in Finland – Takes over local distribution with BioGaia brand
Starting in Q3 2021, BioGaia’s products will be sold under the BioGaia brand in Finland, due to the termination...
Read moreResearch funding for prevention of antibiotic resistance
PAR Foundation (The Foundation to Prevent Antibiotic Resistance), initiated by BioGaia, has granted a total of SEK 3 million to...
Read more